Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics is positioned for durable growth because Auvelity is the first and only oral NMDA receptor antagonist approved for MDD, is still only 0.25% penetrated in a ~21M-patient market, and has already produced 2Q26 net sales of $180.3M, up 51% year over year. The recent April 2026 approval in Alzheimer’s disease agitation expands Auvelity into a second large indication with ~100% Medicare Part D coverage and strong early traction, including a 126% rise in new-to-brand prescriptions among patients 65+ over the first eight weeks. Beyond Auvelity, the company has a de-risked CNS pipeline with near-term catalysts such as AXS-12, solriamfetol, and AXS-14, while shared commercial infrastructure should support favorable margins and approaching cash flow positivity in 2027E.

Axsome Therapeutics is a highly concentrated CNS story whose revenue is overwhelmingly dependent on Auvelity, leaving the company exposed to any slowdown in MDD growth, payer pushback, or tougher competition from cheap generics and branded alternatives. The fundamentals also look fragile because Auvelity script growth has decelerated from 46% to 34% y/y across 3Q25 to 2Q26, prescriber breadth may already be flattening at about 69,000 prescribers, and ADA commercialization faces lower persistence, heavy education needs, and uncertain LTC uptake. On top of that, Symbravo is still only generating about $10-20M in annual sales while requiring formulary concessions, and the business faces meaningful GTN pressure, Medicare IRA risk beginning in 2032, and ongoing financing and dilution risk typical of biotech.